Blocking of MAPK, PI-3K and NF-κB pathways can cause apoptosis and reduce the expression of Mcl-1, suggesting that Mcl-1 as a new target for clinical anti-ESCC therapy. Here, MCL1 is linked to esophageal squamous cell carcinoma.